Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma

Cancer Cell

Volumn 30, Issue 1, 2016, Pages 161-175

  Gomes, Ana L ^a   Teijeiro, Ana ^a   Burén, Stefan ^a   Tummala, Krishna S ^a   Yilmaz, Mahmut ^a   Waisman, Ari ^b   Theurillat, Jean Philippe ^c   Perna, Cristian ^d   Djouder, Nabil ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; FATTY ACID; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNCONVENTIONAL PREFOLDIN RPB5 INTERACTOR; IL17A PROTEIN, HUMAN; SIGNAL PEPTIDE; URI1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; FATTY LIVER; GENE SILENCING; HEPATITIS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFLAMMATION; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL CARCINOMA; LYMPHOCYTE DIFFERENTIATION; METABOLISM; MOLECULAR BIOLOGY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TH17 CELL; VIRUS HEPATITIS; WHITE ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIPID DIET; LIVER NEOPLASMS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DIET, HIGH-FAT; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE; NEUTROPHIL INFILTRATION; NON-ALCOHOLIC FATTY LIVER DISEASE; TH17 CELLS;

EID: 84979774563     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.05.020     Document Type: Article

References (43)

1. Arnold, M., Pandeya, N., Byrnes, G., Renehan, A.G., Stevens, G.A., Ezzati, M., Ferlay, J., Miranda, J.J., Romieu, I., Dikshit, R., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16 (2015), 36–46.
2. Bjornsson, E., Lindberg, J., Olsson, R., Liver reactions to oral low-dose tetracyclines. Scand. J. Gastroenterol. 32 (1997), 390–395.
3. Blonsky, J.J., Harrison, S.A., Review article: nonalcoholic fatty liver disease and hepatitis C virus—partners in crime. Aliment. Pharmacol. Ther. 27 (2008), 855–865.
4. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., Forster, I., Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8 (1999), 265–277.
5. Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits”?. Gastroenterology 114 (1998), 842–845.
6. Deboyser, D., Goethals, F., Krack, G., Roberfroid, M., Investigation into the mechanism of tetracycline-induced steatosis: study in isolated hepatocytes. Toxicol. Appl. Pharmacol. 97 (1989), 473–479.
7. Di Tommaso, L., Franchi, G., Park, Y.N., Fiamengo, B., Destro, A., Morenghi, E., Montorsi, M., Torzilli, G., Tommasini, M., Terracciano, L., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45 (2007), 725–734.
8. Donath, M.Y., Schumann, D.M., Faulenbach, M., Ellingsgaard, H., Perren, A., Ehses, J.A., Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31:Suppl 2 (2008), S161–S164.
9. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
10. El Malki, K., Karbach, S.H., Huppert, J., Zayoud, M., Reissig, S., Schuler, R., Nikolaev, A., Karram, K., Munzel, T., Kuhlmann, C.R., et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J. Invest. Dermatol. 133 (2013), 441–451.
11. Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J.J., Garrone, P., Garcia, E., Saeland, S., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183 (1996), 2593–2603.
12. Gregor, M.F., Hotamisligil, G.S., Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29 (2011), 415–445.
13. Gruben, N., Shiri-Sverdlov, R., Koonen, D.P., Hofker, M.H., Nonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison?. Biochim. Biophys. Acta 1842 (2014), 2329–2343.
14. Guo, X., Xiong, L., Sun, T., Peng, R., Zou, L., Zhu, H., Zhang, J., Li, H., Zhao, J., Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn. Pathol., 7, 2012, 44.
15. Harley, I.T., Stankiewicz, T.E., Giles, D.A., Softic, S., Flick, L.M., Cappelletti, M., Sheridan, R., Xanthakos, S.A., Steinbrecher, K.A., Sartor, R.B., et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 59 (2014), 1830–1839.
16. He, G., Yu, G.Y., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., Sieghart, W., Peck-Radosavljevic, M., Leffert, H.L., Karin, M., Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17 (2010), 286–297.
17. He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S.E., Jepsen, K., et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155 (2013), 384–396.
18. Huh, J.R., Leung, M.W., Huang, P., Ryan, D.A., Krout, M.R., Malapaka, R.R., Chow, J., Manel, N., Ciofani, M., Kim, S.V., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 472 (2011), 486–490.
19. Korn, T., Bettelli, E., Oukka, M., Kuchroo, V.K., IL-17 and Th17 cells. Annu. Rev. Immunol. 27 (2009), 485–517.
20. Lafdil, F., Miller, A.M., Ki, S.H., Gao, B., Th17 cells and their associated cytokines in liver diseases. Cell Mol. Immunol. 7 (2010), 250–254.
21. Lo, R.C., Ng, I.O., Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin. J. Cancer Res. 23 (2013), 245–253.
22. Marengo, A., Rosso, C., Bugianesi, E., Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu. Rev. Med. 67 (2016), 103–117.
23. Miyamoto, M., Prause, O., Sjostrand, M., Laan, M., Lotvall, J., Linden, A., Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J. Immunol. 170 (2003), 4665–4672.
24. Mraz, M., Haluzik, M., The role of adipose tissue immune cells in obesity and low-grade inflammation. J. Endocrinol. 222 (2014), R113–R127.
25. Nagle, C.A., Klett, E.L., Coleman, R.A., Hepatic triacylglycerol accumulation and insulin resistance. J. Lipid Res. 50:Suppl (2009), S74–S79.
26. Nascimento, A.C., Maia, D.R., Neto, S.M., Lima, E.M., Twycross, M., Baquette, R.F., Lobato, C.M., Nonalcoholic fatty liver disease in chronic hepatitis B and C patients from Western Amazon. Int. J. Hepatol., 2012, 2012, 695950.
27. Osada, T., Nagashima, I., Tsuno, N.H., Kitayama, J., Nagawa, H., Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma. J. Hepatol. 33 (2000), 247–253.
28. Park, E.J., Lee, J.H., Yu, G.Y., He, G., Ali, S.R., Holzer, R.G., Osterreicher, C.H., Takahashi, H., Karin, M., Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140 (2010), 197–208.
29. Patel, P.S., Buras, E.D., Balasubramanyam, A., The role of the immune system in obesity and insulin resistance. J. Obes., 2013, 2013, 616193.
30. Perry, R.J., Samuel, V.T., Petersen, K.F., Shulman, G.I., The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510 (2014), 84–91.
31. Rowan, A.G., Fletcher, J.M., Ryan, E.J., Moran, B., Hegarty, J.E., O'Farrelly, C., Mills, K.H., Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J. Immunol. 181 (2008), 4485–4494.
32. Sadik, C.D., Kim, N.D., Luster, A.D., Neutrophils cascading their way to inflammation. Trends Immunol. 32 (2011), 452–460.
33. Sun, Y., Asnicar, M., Saha, P.K., Chan, L., Smith, R.G., Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 3 (2006), 379–386.
34. Takahashi, Y., Soejima, Y., Fukusato, T., Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 18 (2012), 2300–2308.
35. Talukdar, S., Oh da, Y., Bandyopadhyay, G., Li, D., Xu, J., McNelis, J., Lu, M., Li, P., Yan, Q., Zhu, Y., et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 18 (2012), 1407–1412.
36. Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (2010), 1836–1846.
37. Tummala, K.S., Gomes, A.L., Yilmaz, M., Grana, O., Bakiri, L., Ruppen, I., Ximenez-Embun, P., Sheshappanavar, V., Rodriguez-Justo, M., Pisano, D.G., et al. Inhibition of de novo NAD(+) synthesis by oncogenic uri causes liver tumorigenesis through DNA damage. Cancer Cell 26 (2014), 826–839.
38. Uenishi, T., Kubo, S., Yamamoto, T., Shuto, T., Ogawa, M., Tanaka, H., Tanaka, S., Kaneda, K., Hirohashi, K., Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 94 (2003), 851–857.
39. Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P.R., Kozma, S.C., Auwerx, J., Thomas, G., Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004), 200–205.
40. Wolf, M.J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. Metabolic activation of intrahepatic CD8(+) T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26 (2014), 549–564.
41. Zhang, H., Qian, D.Z., Tan, Y.S., Lee, K., Gao, P., Ren, Y.R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA 105 (2008), 19579–19586.
42. Zhao, Y.J., Ju, Q., Li, G.C., Tumor markers for hepatocellular carcinoma. Mol. Clin. Oncol. 1 (2013), 593–598.
43. Zhao, L., Zhong, S., Qu, H., Xie, Y., Cao, Z., Li, Q., Yang, P., Varghese, Z., Moorhead, J.F., Chen, Y., Ruan, X.Z., Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Sci. Rep., 5, 2015, 10222.